Abstract
The high dose chemotherapy and radiation typically used as the preparative regimen for bone marrow transplantation produces considerable morbidity and mortality, and limits the use of this modality to a minority of patients who are young and in good general medical condition. Recent experimental and clinical data indicate that, in addition to the cytotoxic effect of the preparative regimen, an immune-mediated effect significantly contributes to the therapeutic benefit of allogeneic stem cell transplantation. This has been well documented in animal models1,2 and in human clinical transplantation. Higher risk of relapse goes after T-cell-depleted 3,4 or syngeneic transplant.5,6 Also there is reduced risk of leukemia relapse in patients with acute and chronic graft-versus-host disease (GVHD).7,8 Elimination of residual disease, as detected by cytogenetics or polymerase chain reactions techniques in diseases such as chronic myelogenous leukemia (CML) which may take six to twelve months after transplant presumably due to an ongoing graft-versus-leukemia effect.9 Withdrawal of immunosuppression given for prevention of GVHD can occasionally lead to restoration of remission in patient relapsing after transplants.10 However, the most direct evidence of this graft-versus-malignancy (GVM) effect is the observation that infusion of donor lymphocytes can re-induce remission in patients who relapse after allogeneic transplantation.11,12 This GVM has been shown in myeloid diseases where is has been most effective against CML and to a lesser extent in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). They have also been shown in multiple myeloma13,14 chronic lymphocytic leukemia (CLL),15 low grade lymphoma16 and solid tumors.17,18
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bortin MM, Rimm AA, Saltztein EC: Graft versus leukemia: Quantification of adoptive immunotherapy in murine leukemia.Science1973, 179:811–813.
Truiit R, LeFever A, Shih CY: Graft-versus leukemia reactions: Experimental models and clinical trials. InProgress in Bone marrow Transplantation.Edited by Gale RP, Champlin RE, New York: Alan R Liss; 1987:219–232.
Horowitz M, Gale R, Sondel PM, et al.: Graft-versus leukemia reactions after bone marrow transplantation.Blood1990, 75:555–562.
Goldman J, Gale R, Horowitz MM, et al.: Bone marrow transplantation for chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806–814.
Fefer A, Cheever MA, Greenberg PD: Identical-twin bone marrow (syngeneic) transplantation for hematologic cancers.J Natl Cancer Inst1986, 76:1269–1271.
Gale RP, Horowitz MM, Ash RC, et al.: Identical twin bone marrow transplantation or leukemia.Ann Intern Med1994, 120:646–652.
Weiden P, Flournoy N, Thomas E, et al.: Antileukemic effect of graftversus-host disease in human recipients of allogeneic marrow grafts.N EnglJMed1979, 300:1068–1073.
Sullivan K, Storb R, Bucker CD, et al.: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms.NEngl JMed1989, 320:828–834.
Radich JP, Gehly G, Gooley T, et al.: Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse.Blood1991, 77:874–878.
Collins RG, Rogers ZR, Bennet M, et al.: Hematologic relapse of chronic myelogenous leukemia following allogeneic transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression.Bone Marrow Transplant1992, 10:391–395.
Kolb HJ, Schattenberg A, Goldman JM, et al.: Graft-versus-leukemia effect of donor lymphocyte infusions in marrow grafted patients.Blood1995, 86:2041–2050.
Collins RH, Shpilberg O, Drobyski WR, et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.J Clin Oncol1997, 15:433–444.
Tricot G, Vesole DH, Jagannath S, et al.: Graft-versus-myeloma effect: proof of principal.Blood1996, 87:1196–1198.
Lokhorst HM, Schattenberg A, Comelissen JJ, et al.: Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.Blood1997, 90:4206–4211.
Rondon G, Giralt S, Huh Y, et al.: Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia.Bone Marrow Transplant1996, 18:669–672.
Khouri I, Keating MJ, Korbling M, et al.: Transplant lite: Induction of graft vs malignancy using fludarabine based nonablative chemotherapy and allogeneic progenitor-cell transplantation as treatment for lymphoid malignancies.J Clin Oncol1998, 16:2817–2824.
Ueno NT, Rondon G, Mizra NQ, et al.: Allogeneic peripheral blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.J Clin Oncol1998, 16:986–993.
Childs R, Clave E, Contentin N, et al.: Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.Blood1999, 94:3234–3241.
Giralt S, Estey E, Albitar M, et al.: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.Blood1997, 89:4531–4536.
Slavin S, Nagler A, Naparstak E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic disease.Blood1998, 91:756–763.
Plunkett W, Sanders P: Metabolism and action of purine nucleoside analogs.Pharmacol Ther1991, 49:239–245.
Estey E, Plunkett W, Gandhi V, et al.: Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.Leuk Lymphoma1993, 9:343–350.
Kornblau S, Gandhi V, Andreeff M, et al.: Clinical and laboratory studies of 2-chlorodeoxyadenosine + cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.Leukemia1996, 10:1563–1569.
Przepiorka D, Smith TL, Folloder J, et al.: Risk factors for acute graftversus-host disease after allogeneic blood stem cell transplantation.Blood1999, 4:1465–1470.
Giralt S, Cohen A, Mehra R, et al.: Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning [abstract].Blood1997, 90:417a.
Sarosy G, Leyland-Jones B, Soochan P, Cheson BD: The systemic administration of intravenous melphalan.J Clin Oncol1988, 6:17681782.
Li L, Keating MJ, Plunket W, Yang LY: Fludarabine-mediated repair inhibition of cisplatin induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.Modular Pharmacol1997, 52:798–806.
Moreau P, Fiere D, Bezwoda WR, et al.: Prospective randomized placedo-controlled study of granulocyte-macrophage colongystimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.J Clin Oncol1997, 15:660–666.
Van Besien K, Sobocinski KA, Rowlings PA, et al.: Allogeneic bone marrow transplantation for low-grade lymphoma.Blood1998, 92:1832–1836.
Verdonck LF, Dekker AW, Lokhorst HM, et al.: Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma.Blood1997, 90:4201–4205.
Van Besien KW, Khouri IF, Giralt SA, et al.: Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.JClin Oncol1995, 13:1096–1102.
Khouri I, Lee M-S, Palmer L, et al.: Transplant-lite using fludarabinecyclophosphamide (FC) and allogeneic stem cell transplant (alloSCT) for low-grade lymphoma (LGL).Blood1999, 94 (suppl 1, part I abstr), 348a.
Phillip T, Guglielmi C, Hagenbeek A, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin’s lymphoma.N Engl J Med1995, 333:1540–1545.
Ratanatharathorn V, Uberti J, Karanes C, et al.: Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphoma.Blood1994, 84:1050–1055.
Chopra R, Goldstone AH, Pearce R, et al.: Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: A case controlled analysis of the European Bone Marrow Transplant Registry data.JClin Oncol1992, 10:1690–1695.
Khouri I, Giralt S, Saliba R, et al.: “Mini”-allogeneic stem cell transplantation for relapsed/refractory lymphomas with aggressive histologies.Proceedings of the American Society of Clinical Oncology2000, 19:47a.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Khouri, I., Giralt, S., Champlin, R. (2002). Non-Myeloablative Allogeneic Hematopoietic Transplantation and Induction of Graft-Versus-Malignancy. In: Bashey, A., Ball, E.D. (eds) Non-Myeloablative Allogeneic Transplantation. Cancer Treatment and Research, vol 110. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0919-6_7
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0919-6_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5304-1
Online ISBN: 978-1-4615-0919-6
eBook Packages: Springer Book Archive